Roche Molecular Systems Company

Roche Molecular Systems, Inc., a molecular diagnostics company, develops and commercializes diagnostic and blood screening tests based on polymerase chain reaction (PCR) technologies. Its products include in vitro diagnostic PCR kits, research assays, and associated technology platforms, including options that enable the automation of the PCR process. It offers diagnostic and research assays in the areas of virology, blood screening, women's health, HPV and chlamydia trachomatis/neisseria gonorrhoeae, and microbiology and genomics, as well as develops tests in the area of oncology. The company also provides PCR-based nucleic acid tests and automation that enables the detection of active HIV, Hepatitis C, and Hepatitis B infections, as well as enables to reduce transmission of these diseases during transfusions, transplantations, or administration of other medical therapies derived from blood products. In addition, it offers clinical laboratory system, which combines CE-marked in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology. The company was incorporated in 1991 and is headquartered in Pleasanton, California. It has research, development, manufacturing, and distribution facilities in the United States, Germany, and Switzerland. Roche Molecular Systems, Inc. operates as a subsidiary of Roche Diagnostics Corporation.
Technology: Personalized Diagnostics
Industry: Precision Medicine
Headquarters: Pleasanton
Founded Date: 1991
Employees Number: 10001+
Funding Status: undisclosed

Visit Website
https://www.twitter.com/roche
Register and Claim Ownership